Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
A phase 2 trial of Savolitinib and Durvalumab in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.
Overview
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC is a phase 2 interventional study registered as NCT05374603 by AstraZeneca, with 47 participants enrolled, started 2022-11-15 and due to reach its primary completion in 2027-01-18. Interventions recorded: Savolitinib and Durvalumab.
Similar pages
not linked directly; found by shared links- TrialSafety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
Shares Durvalumab, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
Shares Durvalumab, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialOsimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Shares Savolitinib, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Shares Durvalumab, AstraZeneca and the tag pipeline.
- TrialDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Shares Durvalumab, AstraZeneca and the tag pipeline.
- TrialDurvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Shares Durvalumab, AstraZeneca and the tag pipeline.
- TrialOsimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
Shares Durvalumab, AstraZeneca and the tag pipeline.